Anti-SARS-CoV-2 Antibody Products
Last Updated: February 11, 2021
- There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of the following products for the treatment of COVID-19:
- COVID-19 convalescent plasma
- The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for hospitalized patients with COVID-19 (see Convalescent Plasma for more details).
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins
- There are currently insufficient data for the Panel to recommend either for or against the use of the following anti-SARS-CoV-2 monoclonal antibodies for the treatment of nonhospitalized patients with mild to moderate COVID-19:
- The combination of casirivimab plus imdevimab
- The FDA has issued EUAs for the use of bamlanivimab and the casirivimab plus imdevimab combination for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression (see Anti-SARS-CoV-2 Monoclonal Antibodies for more details).
- The FDA also recently issued an EUA for bamlanivimab plus etesevimab for the treatment of certain nonhospitalized patients with mild to moderate COVID-19; the Panel will issue recommendations on the use of this combination shortly.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion